These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
227 related items for PubMed ID: 32434781
1. Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis. Ziegler K, Rath A, Schoerner C, Meyer R, Bertsch T, Erbguth F, Bogdan C, Steinmann J, Held J. J Clin Microbiol; 2020 Aug 24; 58(9):. PubMed ID: 32434781 [Abstract] [Full Text] [Related]
5. Discriminating between Lyme neuroborreliosis and other central nervous system infections by use of biomarkers CXCL13 and IL-6. Leth TA, Dessau RB, Møller JK. Ticks Tick Borne Dis; 2022 Sep 24; 13(5):101984. PubMed ID: 35709639 [Abstract] [Full Text] [Related]
8. CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. Ljøstad U, Mygland A. J Neurol; 2008 May 24; 255(5):732-7. PubMed ID: 18344056 [Abstract] [Full Text] [Related]
10. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. Hytönen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. J Neuroinflammation; 2014 Jun 11; 11():103. PubMed ID: 24920219 [Abstract] [Full Text] [Related]
13. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis. Rupprecht TA, Manz KM, Fingerle V, Lechner C, Klein M, Pfirrmann M, Koedel U. Clin Microbiol Infect; 2018 Dec 11; 24(12):1234-1240. PubMed ID: 29674128 [Abstract] [Full Text] [Related]
15. Sensitivity and specificity of cerebrospinal fluid CXCL13 for diagnosing Lyme neuroborreliosis - a study on 1410 patients and review of the literature. Lintner H, Hochgatterer-Rechberger P, Pischinger B, Seier J, Vollmann P, Haushofer A, Rittner H, Sommer C, Topakian R. J Neurol Sci; 2020 Jul 15; 414():116843. PubMed ID: 32344220 [Abstract] [Full Text] [Related]
16. Point-of-care testing for CXCL13 in Lyme neuroborreliosis. Pietikäinen A, Oksi J, Hytönen J. Diagn Microbiol Infect Dis; 2018 Jul 15; 91(3):226-228. PubMed ID: 29567125 [Abstract] [Full Text] [Related]
17. Chemokine CXC Ligand 13 in Cerebrospinal Fluid Can Be Used as an Early Diagnostic Biomarker for Lyme Neuroborreliosis: A Meta-Analysis. Yang J, Han X, Liu A, Bao F, Peng Y, Tao L, Ma M, Bai R, Dai X. J Interferon Cytokine Res; 2017 Oct 15; 37(10):433-439. PubMed ID: 28972436 [Abstract] [Full Text] [Related]
18. The B-lymphocyte chemokine CXCL13 in the cerebrospinal fluid of children with Lyme neuroborreliosis: associations with clinical and laboratory variables. Barstad B, Tveitnes D, Dalen I, Noraas S, Ask IS, Bosse FJ, Øymar K. Infect Dis (Lond); 2019 Oct 15; 51(11-12):856-863. PubMed ID: 31573360 [Abstract] [Full Text] [Related]
19. Cerebrospinal fluid chemokine CXCL13 in the diagnosis of neuroborreliosis in children. Sillanpää H, Skogman BH, Sarvas H, Seppälä IJ, Lahdenne P. Scand J Infect Dis; 2013 Jul 15; 45(7):526-30. PubMed ID: 23521134 [Abstract] [Full Text] [Related]
20. CSF B - lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. Ljøstad U, Mygland Å. J Neurol; 2008 May 15; 255(5):782. PubMed ID: 27517589 [Abstract] [Full Text] [Related] Page: [Next] [New Search]